Vous êtes sur la page 1sur 16

Our Team

Michael Gara, M.S., MBA Breanne Przestrzelski, B.S., PhD. Student Dr. Brian McKinley, M.D. James Chow, B.S., PhD. Candidate (5/14) Alison Lamb, B.S., MBA Student Joseph Holland, B.S., J.D., MBA Student Chief Executive Officer Chief Marketing Officer Chief Medical Officer Chief Technical Officer Chief Operating Officer Chief Financial Officer & General Counsel Facilities Consultant COO Kiyatec & Advisor

Luke Pietrykowski Dr. David Orr, PhD., MBA

EXECUTIVE SUMMARY
Multi-patent protected platform technology Three different products into three different markets NEST BCS tissue integrative chemo preventive first in class Near term (2-3 yr.) product introduction to generate cash flow with $1.5M in year 6 accelerating to $102M by year 10 Minimal upfront investment (<$4M) leveraged with non-dilutive funding of $2.5M Experienced CEO, CTO, CMO and world class Board members for guidance Located in a new bioengineering facility with low cost, business friendly state and ready access to clinical and university partners

Our Products & Company


First product to market- NEST-TF, injectable collagen based tissue augmentation product sold into aesthetic, trauma, surgical markets for superior native tissue integration and minimal inflammation Second product, NEST-DX, novel point of use diagnostic platform to aid in determination of surgical margins in cancer patients Third product, NEST-BCS, first of its kind injectable tissue augmentation product for post-lumpectomy that also decreases the rate of recurrence NEST maintains intellectual property rights but outsources manufacturing and distribution Initially will market all three products through strategic partnerships with leaders in the various markets we serve to conserve cash

Current Treatments -Primary treatment is removal of tumor via lumpectomy or mastectomy


-Postoperational radiation therapy given to patients undergoing breast conserving surgery (BCS) -Other adjuvant therapies include anti-hormone drug administration such as tamoxifen and anastrozole

Surgical Extirpation

Radiation Therapy

Hormonal Therapies

Current R&D for Restoration and Cosmesis

Autologous Flap Procedure

Saline/Silicone Implant

Fat Grafting

Decellularized Dermal Matrix

Decellularized Adipose Tissue

Cytori System Fat + Stem Cells

NEST R&D
NEST-Tissue Fill
An injectable and biocompatible hydrogel for breast reconstruction after oncologic surgery Utilizes patented tissue engineering composite technology for adipose tissue regeneration and repair Current Status: Preclinical Animal Studies Regulatory Pathway: 510K (Premarket Notification) Time to Market: 1-2 years

NEST-BCS
A naturally derived product which combines the regenerative properties of NEST-Tissue Fill with the anti-cancer properties of Penta-galloyl Glucose to prevent cancer recurrence Current Status: Product Development Phase Regulatory Pathway: PMA (Premarket Approval) Time to Market: 4-5 years A powerful diagnostic tool for rapid out-patient early breast cancer detection Utilizes patented wicking fiber technology to accelerate cell migration into optical detection zones Current Status: Product Development Phase Regulatory Pathway: 510K (Premarket Notification) Time to Market: 2-3 years

NEST-Dx

Market Analysis
Breast Surgical Oncology
$88 billion (global-2008)
$16.5 billion (US-2010) 234,580 new cases/yr 95% of cancers occur after age 40 Global Breast Cancer Market
Cancer Therapy Diagnostics and Drug Technologies

NEST-BCS
Radiation Therapy Proportion of sites that budget $2M from 13% (2012) to 24% (2014) Chemotherapy $42 billion (US-2006) 150% growth rate in bilateral mastectomies (1998-2003)

By 2030, 72 million will be 65 or older


Immediate reconstruction from 21% to 38% (19982008) 20-40% undergo reconstruction

NEST-Tissue Fill
Facial Aesthetic Dermal Injectable Products--

NEST-Dx
$21.2 billion (US-2010)
2.5% CAGR $24 billion by 2016 0.5% chance of local recurrence/yr
Dermal Injectable Fillers

$860 million (US2010)


Cosmetic plastic surgery, facial aesthetics, and medical lasers-$3 billion by 2017 Global bio-implants-- CAGR 7.3% (2012-2017)

Competitive Analysis
1. RECONSTRUCTION Breast Implants DIEP/SIEA/SGAP Flaps TRAM Flap Oncoplastic Surgery NEST-Tissue Fill 2. PREVENTION OF RECURRENCE Radiation Bilateral Mastectomy NEST-BCS

NEST : (1) Ability to reduce breast cancer recurrence (2) Natural breast tissue reconstructive benefits (3) Anti-metastatic properties

No other technology allows for reconstructive benefits for the potential of natural tissue regrowth following breast cancer surgical removal

Business Model and Growth Strategy


Growth Strategy Staged Product Development

Exit Strategy License individual patents or sell company to partner

Investments - Angel Networks

- SBIR Grants

-SC Economic Development Grants

Operational Plan
Location/Inventory/Distribution
Greenville, SC Research Lab & Offices: Independent Sales and Distributors

Back Office Operations


Team Members Add 5 employees 1st year (R&D)

Strategic Partnerships
NEST-DX: partner with an optical sensing company Strategic Marketing Partnerships for NEST-TF and NEST-BCS AVON Foundation For Women National Cancer Institute The Center for Advancing Innovation Department of Defense

Commercialization & Licensing


NEST will license three patents from Clemson Patent #6991652-Tissue engineering constructs for NEST-TF & NEST-BCS Patent # 8293531 3D Ex-vivo Tissue Construct for NEST-DX Patent Application Use of Pentagalloyl Glucose as cross linking agent

NEST will manufacture product and partner with existing leaders in their respective markets
Diagnostic for NEST-DX, e.g. Grace, Quest, etc. Tissue Augmentation for NEST-TF, e.g. Synthes, Allergan, Medicis, etc. Breast Cancer Market for NEST-BCS, e.g. Eli Lilly, Celgene, Novartis, etc.

NEST will split profits with these companies and retain all product improvement rights

Risk Mitigation
Technology Risk
In-vivo large animal studies good results In-vitro tests indicate product will induce apoptosis breast cancer cell lines Predicate products for NEST-TF and rapid development of NEST-DX will have low regulatory hurdles

Market Risk
Three products across multiple markets Designed to be user friendly and differentiated

Regulatory Risk
No NCE in formulations and NEST-DX ex-vivo use

Financial Risk
Minimal equity financing ($1M) and access to non-dilutive $ (NCI,DOD,SC)

Management Risk
Experienced CEO, CMO and world class SAB & BOD (several committed)

Financial Highlights
Positive NOI beginning in 2016, year 3, once product sales commence Positive Burn Rate from the start in year 2014, which annually increases through year 2023 Mostly non-dilutive financing from SBIR grants (NCI & DOD) and SC Economic Development grants By 2023, combined sales for all three products are expected to be more than $102M
2015 -$1,749,600 2016 $255,250 2017 $541,038 2018 $976,193 2019 $1,521,262 2020 $14,956,570 2021 $27,821,280 2022 $52,916,052 2023 $102,306,505

2014 Cash Flows from Operating Activities Total NOI -$696,850 Cash Flows from Financing Activities Avon $1,000,000 SBIR $150,000 SBIR $150,000 NCI Bridge Fund Grant SC Launch Funding $100,000 Total Financing Burn Rate $1,400,000 $703,150

$1,000,000 $1,000,000 $1,000,000 $100,000 $2,100,000 $350,400 $1,000,000 $1,255,250 $541,038 $976,193 $1,521,262 $14,956,570 $27,821,280 $52,916,052 $102,306,505

Conclusions
Why is NEST an attractive investment?
Our products:
NEST-Dx NEST-TF NEST-BCS

NEST-Dx and NEST-TF to market in 2-3 years


Low regulatory hurdles: 510K

NEST-BCS: Revolutionary Strong patent portfolio and collaborations Strategic partnerships Strong Management Team

Pro-forma P&L
2014 Sales NEST Dx NEST TF NEST BCS Total Sales Cost of Goods Sold NEST Dx NEST TF NEST BCS Gross Margin Nest Dx NEST TF NEST BCS Total Gross Margin Expenses Rent Payroll Equipment SG&A Clincal Expense Total Expenses Total NOI 2015 2016 2017 $1,500,000 $5,750,000 2018 $1,965,000 $6,612,500 2019 $2,574,150 $7,604,375 2020 $3,372,137 $8,745,031 $15,000,000 $27,117,168 2021 $4,417,499 $10,056,786 $30,000,000 $44,474,285 2022 $5,786,923 $11,565,304 $60,000,000 $77,352,227 2023 $7,580,870 $13,300,099 $120,000,000 $140,880,969 $5,000,000

$5,000,000

$7,250,000

$8,577,500

$10,178,525

$2,000,000

$450,000 $2,300,000

$589,500 $2,645,000

$772,245 $3,041,750

$1,011,641 $3,498,013 $1,500,000

$1,325,250 $4,022,714 $3,000,000

$1,736,077 $4,626,122 $6,000,000

$2,274,261 $5,320,040 $12,000,000

$3,000,000

$1,050,000 $3,450,000

$1,375,500 $3,967,500

$1,801,905 $4,562,625

$2,360,496 $5,247,019 $13,500,000 $21,107,514

$3,092,249 $6,034,072 $27,000,000 $36,126,321

$4,050,846 $6,939,182 $54,000,000 $64,990,029

$5,306,609 $7,980,060 $108,000,000 $121,286,668

$3,000,000

$4,500,000

$5,343,000

$6,364,530

$46,000 $487,500 $100,000 $63,350 $696,850 ($696,850)

$46,000 $975,000 $115,000 $113,600 $ 500,000 $1,749,600 ($1,749,600)

$150,000 $1,462,500 $132,250 $500,000 $500,000 $2,744,750 $255,250

$150,000 $1,681,875 $152,088 $725,000 $1,250,000 $3,958,963 $541,038

$150,000 $1,934,156 $174,901 $857,750 $1,250,000 $4,366,807 $976,193

$150,000 $2,224,280 $201,136 $1,017,853 $1,250,000 $4,843,268 $1,521,262

$150,000 $2,557,922 $231,306 $2,711,717 $500,000 $6,150,944 $14,956,570

$150,000 $2,941,610 $266,002 $4,447,428 $500,000 $8,305,040 $27,821,280

$150,000 $3,382,851 $305,902 $7,735,223 $500,000 $12,073,976 $52,916,052

$150,000 $3,890,279 $351,788 $14,088,097 $500,000 $18,980,164 $102,306,505